CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
Lenalidomide +2 moredrug
Likely dose
Lenalidomide 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01079936
NCT01079936Phase 2Completed
CompareCT.gov

Phase I/II Study Of The Combination Of Lenalidomide With High-Dose Melphalan For Autologous Transplant in Patients With Multiple Myeloma

M.D. Anderson Cancer Center·interventional·Posted Mar 3, 2010·Updated Jun 6, 2016

In Brief

A Phase 2 clinical trial evaluating Lenalidomide, Melphalan, and 1 other intervention for Myeloma and Stem Cell Transplantation. Completed, enrolled 61 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of Revlimid (lenalidomide) and high-dose Alkeran (melphalan) that can be given to patients with multiple myeloma who will receive an autologous stem cell transplantation. The safety of this combination therapy will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyeloma, Stem Cell Transplantation
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 3, 2010
Enrollment StartMar 1, 2010
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 16.3 years ago

Interventions

Lenalidomidedrug

Beginning dose level 25 mg by mouth (PO) on Days -8 to -2

Melphalandrug

Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion

Stem Cell Infusionprocedure

Stem cell infusion on Day 0.